Genomewide Association Study of Statin‐Induced Myopathy in Patients Recruited Using the UK Clinical Practice Research Datalink. Issue 6 (31st July 2019)

• Record Type: Journal Article
• Authors: Carr, Daniel F.; Francis, Ben; Jorgensen, Andrea L.; Zhang, Eunice; Chinoy, Hector; Heckbert, Susan R.; Bis, Joshua C.; Brody, Jennifer A.; Floyd, James S.; Psaty, Bruce M.; Molokhia, Mariam; Lapeyre‐Mestre, Maryse; Conforti, Anita; Alfirevic, Ana; van Staa, Tjeerd; Pirmohamed, Munir
• Is Part Of: Clinical pharmacology & therapeutics. Volume 106:Issue 6(2019)
• Page Start: 1353
• Page End: 1361
• Publication Date: 2019-07-31
• Subjects: Pharmacology -- Periodicals; Therapeutics -- Periodicals; 615.5
• DOI: 10.1002/cpt.1557
• Languages: English
• ISSNs: 0009-9236

Abstract

Abstract : Statins can be associated with myopathy. We have undertaken a genomewide association study (GWAS) to discover and validate genetic risk factors for statin‐induced myopathy in a "real‐world" setting. One hundred thirty‐five patients with statin myopathy recruited via the UK Clinical Practice Research Datalink were genotyped using the Illumina OmniExpress Exome version 1.0 Bead Chip and compared with the Wellcome Trust Case‐Control Consortium ( n = 2, 501). Nominally statistically significant single nucleotide polymorphism (SNP) signals in the GWAS ( P < 5 × 10 −5 ) were further evaluated in several independent cohorts (comprising 332 cases and 449 drug‐tolerant controls). Only one (rs4149056/c.521C>T in the SLCO1B1 gene) SNP was genomewide significant in the severe myopathy (creatine kinase > 10 × upper limit of normal or rhabdomyolysis) group ( P = 2.55 × 10 −9 ; odds ratio 5.15; 95% confidence interval 3.13–8.45). The association with SLCO1B1 was present for several statins and replicated in the independent validation cohorts. The data highlight the role of SLCO1B1 c.521C>T SNP as a replicable genetic risk factor for statin myopathy. No other novel genetic risk factors with a similar effect size were identified.